FindTrial
Sign In

Prevalence of COVID19 antibodies among blood donors.

Seroprevalence of SARS-CoV2 Specific IgG Antibodies Among Blood Donors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/01/030455
Enrollment
100
Registered
2021-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Control Intervention1: NIL: NIL

Sponsors

Nivetha M
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All healthy eligible blood donors who are willing to Participate in the study

Exclusion criteria

Exclusion criteria: Blood Donors who are not willing to participate in the study.

Design outcomes

Primary

MeasureTime frame
Estimating the prevalence of asymptomatic Covid 19 infections among blood donorsTimepoint: 1 year—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactNivetha M

Sri Ramachandra institute of higher education and research.

rrkm05@gmail.com9840417591

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026